Swedish biotechnology company Neogap Therapeutics, which is developing personalised immunotherapy, announces its acquisition of the remaining 30 percent of the shares in its subsidiary, TCER Oncology AB. This acquisition will broaden Neogap’s patent portfolio and strengthen the company’s pipeline of potential drug candidates, further consolidating Neogap’s position in the field.

Previously, Neogap owned 70 percent of the shares in TCER Oncology AB. During the second quarter of this year, the remaining 30 percent was acquired from Rolf Kiessling and Stina Wickström in exchange for Neogap shares. This means that Rolf Kiessling and Stina Wickström, both prominent researchers in the company’s field, are now shareholders in Neogap, further enhancing the company’s scientific expertise. Rolf Kiessling is well-known for his discovery of NK cells, which have had significant implications in cancer research and the development of cancer therapies.

The acquisition not only expands Neogap’s patent portfolio but also enhances the company’s pipeline of potential candidates for future preclinical and clinical development.

In recent years, Neogap has enjoyed a successful academic collaboration with Rolf Kiessling and Stina Wickström to investigate how the company’s EpiTCer^® beads can be used to stimulate dendritic cells and activate tumor-specific T cells in the patient’s blood. The collaboration has yielded fruitful results, leading to a patent application and the publication of their findings in the reputable scientific journal, Frontiers.

As a result of the acquisition, the patent rights now transfer from Neogap’s subsidiary, TCER Oncology, to Neogap.

“We are delighted to acquire the remaining shares in TCER Oncology and extend a warm welcome to Rolf Kiessling and Stina Wickström as valued shareholders in Neogap. This acquisition marks an important milestone, fortifying our standing in personalised immunotherapy. It allows us to expand our patent portfolio and pipeline of potential drug candidates while further developing our innovations in the field. We look forward to continuing to drive progress and deliver groundbreaking scientific breakthroughs in cancer treatment,” says Samuel Svensson, CEO of Neogap.

Swedish biotechnology company Neogap Therapeutics, which is developing personalised immunotherapy, announces its acquisition of the remaining 30 percent of the shares in its subsidiary, TCER Oncology AB. This acquisition will broaden Neogap’s patent portfolio and strengthen the company’s pipeline of potential drug candidates, further consolidating Neogap’s position in the field.

Previously, Neogap owned 70 percent of the shares in TCER Oncology AB. During the second quarter of this year, the remaining 30 percent was acquired from Rolf Kiessling and Stina Wickström in exchange for Neogap shares. This means that Rolf Kiessling and Stina Wickström, both prominent researchers in the company’s field, are now shareholders in Neogap, further enhancing the company’s scientific expertise. Rolf Kiessling is well-known for his discovery of NK cells, which have had significant implications in cancer research and the development of cancer therapies.

The acquisition not only expands Neogap’s patent portfolio but also enhances the company’s pipeline of potential candidates for future preclinical and clinical development.

In recent years, Neogap has enjoyed a successful academic collaboration with Rolf Kiessling and Stina Wickström to investigate how the company’s EpiTCer^® beads can be used to stimulate dendritic cells and activate tumor-specific T cells in the patient’s blood. The collaboration has yielded fruitful results, leading to a patent application and the publication of their findings in the reputable scientific journal, Frontiers.

As a result of the acquisition, the patent rights now transfer from Neogap’s subsidiary, TCER Oncology, to Neogap.

“We are delighted to acquire the remaining shares in TCER Oncology and extend a warm welcome to Rolf Kiessling and Stina Wickström as valued shareholders in Neogap. This acquisition marks an important milestone, fortifying our standing in personalised immunotherapy. It allows us to expand our patent portfolio and pipeline of potential drug candidates while further developing our innovations in the field. We look forward to continuing to drive progress and deliver groundbreaking scientific breakthroughs in cancer treatment,” says Samuel Svensson, CEO of Neogap.